Clinical Trials Logo

Colitis clinical trials

View clinical trials related to Colitis.

Filter by:

NCT ID: NCT00488774 Terminated - Colitis, Ulcerative Clinical Trials

An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis

Start date: August 2007
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to assess the effects (good and bad) of golimumab (CNTO 148) therapy in participants with active ulcerative colitis (UC) (sores in the colon).

NCT ID: NCT00488631 Completed - Colitis, Ulcerative Clinical Trials

An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis

Start date: September 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of golimumab administered subcutaneously (under the skin) injections in maintenance therapy.

NCT ID: NCT00487539 Completed - Colitis, Ulcerative Clinical Trials

An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis

Start date: August 2007
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to assess the effects (good and bad) of golimumab (CNTO 148) therapy in participants with ulcerative colitis (UC).

NCT ID: NCT00486031 Completed - Ulcerative Colitis Clinical Trials

Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study

Start date: October 2006
Phase: Phase 3
Study type: Interventional

The objective of the study is to evaluate the long-term safety and tolerability of treatment with balsalazide disodium tablets in subjects who are in remission from ulcerative colitis or who have mildly to moderately active UC.

NCT ID: NCT00463619 Completed - Ulcerative Colitis Clinical Trials

Follow-up Study With Retarded Release Phosphatidylcholine in Ulcerative Colitis

Start date: April 2000
Phase: N/A
Study type: Observational

Follow-Up Study with Retarded Release Phosphatidylcholine in Ulcerative Colitis Objectives: The objective of the study is to evaluate the follow up of patients treated with retarded release phosphatidylcholine in three controlled, randomized studies. Main question is to investigate whether treatment with phosphatidylcholine could spare patients the intake of steroids and immunosuppressants without clinical deterioration. Study population: - Retarded release phosphatidylcholine in chronic-active ulcerative colitis. - Retarded release phosphatidylcholine in steroid dependent ulcerative colitis. - Dose finding study for retarded release phosphatidylcholine Outcome parameters: Definition of remission: 1. SCCAI <2,5 2. Likert scale: grade 1 or 2 3. subjective impression of remission: yes/no 4. no blood in stool Definition of relapse: 1. subjective impression: yes/no 2. SCCAI ≥ 5 3. blood in stool Definition of low clinical activity: SCCAI < 5 Primary endpoint: sparing effect of steroids and/or immunosuppressants by rPC in chronic active UC. Secondary endpoints 1. maintenance of continuous remission 2. improvement of disease activity: a. clinical activity (SCCAI) b.life quality (SIBDQ-D) c.Likert Score 3. relapse rate: a. time to first relapse b. clinical activity during relapses c. number of relapses in relation to length of treatment

NCT ID: NCT00463151 Completed - Colitis, Ulcerative Clinical Trials

An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis

Start date: June 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine the safety and efficacy of rebamipide by once daily intracolonial administration at 0 (placebo), 60, 150, or 300 mg for 6 weeks in patients with active ulcerative colitis, who are being treated with oral aminosalicylic acid (ASA).

NCT ID: NCT00457171 Terminated - Ulcerative Colitis Clinical Trials

GI-270384 Study In Patients With Mild To Moderate Ulcerative Colitis

Start date: December 2004
Phase: Phase 1
Study type: Interventional

The aim of this double blind, placebo controlled, study is to evaluate activity consistent with efficacy provided by 14 days administration of GI270384X, and to provide preliminary pharmacokinetics and safety/tolerability of 14 days administration of GI270384X in patients with mild to moderate active ulcerative colitis (UC).

NCT ID: NCT00450086 Completed - Collagenous Colitis Clinical Trials

Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis

Start date: March 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether budesonide or mesalazine is more active in the treatment of collagenous colitis.

NCT ID: NCT00449722 Completed - Ulcerative Colitis Clinical Trials

OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis

Start date: July 2005
Phase: Phase 3
Study type: Interventional

To proof the therapeutic equivalence of once daily (OD) versus three times daily (TID) dosing of total 3.0 g mesalazine granules in patients with active ulcerative colitis

NCT ID: NCT00446849 Completed - Ulcerative Colitis Clinical Trials

Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)

Start date: May 1, 2007
Phase: Phase 4
Study type: Interventional

To evaluate the percentage of subjects with clinical recurrence of UC at 6 months using MMX mesalamine once daily.